drugset / Trial / NCT05164536

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536

Phase 1 Completed 140 enrolled Invicro
NaSingle-groupOpen-labelOther

Summary

The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.

Timeline

Start
2021-08-27
Primary completion
2022-11-08
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject florbetapir F 18 Diagnostic / imaging agent

Indications